News Alert: Algernon Pharmaceuticals: Trial Complete for COVID-19 Treatment
Hopeful that lead compound will be found to reduce severity and duration of covid-19 infection
Algernon Pharmaceuticals is a clinical stage drug repurposing company. On March 6th, 2020, the company announced that it was going to explore the potential of using NP-120 (Ifenprodil) as a novel treatment for COVID-19. An independent research study found that Ifenprodil significantly reduced acute lung injury. It also improved survivability in an animal study with H5N1 infected mice. H5N1 is, in fact, the most lethal form of influenza known to date with an over 50% mortality rate.
Algernon recently concluded a trial for Ifenprodil and is expecting to report on the data by the end of February. They are hopeful that Ifenprodil will be found to reduce the severity as well as the duration of a covid-19 infection.
More About Algernon
Algernon investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. They specifically investigate compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
For more information on Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) please fill out the form below.